Importantly, though the screening was initially conducted on a RET/PTC1-positive cell line (TPC1), subsequent validation experiments proved that sensitivity to knock-down of the 14 genes was shared by most thyroid cancer cell lines harboring different oncogenic lesions (BRAF mutation in BCPAP and 8505C and KRAS mutation in CAL62). The gene discussed is KRAS; the disease is thyroid cancer.